HCA Healthcare Sees Q2 Revenue at $20.23B, Topping Expectations
HCA sits 19% above its 52-week low of $330.
Summary
HCA Healthcare pre-announced Q2 revenue of approximately $20.23 billion, exceeding consensus estimates and signaling strong hospital service demand. The company reported Q2 EPS of $7.62, which includes a 3-cent gain from facility sales, and adjusted EBITDA of about $4.027 billion. Same-facility admissions rose 2.5% and equivalent admissions rose 2.7%, though a payer mix shift toward uninsured volume had a $400 million unfavorable impact on pretax income. The revenue growth implies top-line expansion above the 7.1% full-year 2025 increase, reinforcing positive momentum. With a $10 billion buyback authorization and recent debt offerings, strong operating performance supports shareholder returns. The official Q2 earnings release will provide further margin and volume details.
At the time of this announcement, HCA was trading at $392.00 on NYSE in the Life Sciences sector, with a market capitalization of approximately $86.7B. The 52-week trading range was $330.00 to $556.52. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.